|
|
Vol. 11.38 – 9 October, 2020
|
|
|
|
|
|
|
|
Investigators found that in prostate cancer (PCa), samples from men treated with androgen deprivation therapy, ERβ, and inositol-polyphosphate 4-phosphatase type II (INPP4B) expression were maintained in some samples. To investigate the role of ERβ1 in regulation of INPPB, they engineered the highly metastatic PCa cell line, PC3, to express ERβ1.
[Proceedings of the National Academy of Sciences of the United States of America]
|
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
|
Scientists demonstrated de novo neuroendocrine differentiation of the human prostate luminal epithelial cells induced by caAKT1 and c-Myc and revealed an impact of cellular status on initiation of lineage plasticity.
[Oncogene]
|
|
|
|
|
|
The authors demonstrated that HOX transcript antisense RNA (HOTAIR) promoted invasion and metastasis of prostate cancer by decreasing the inhibitory effect of hepaCAM on MAPK signaling.
[British Journal of Cancer]
|
|
|
|
|
|
Transplantation of CD63-Antares2-expressing prostate cancer cells into mice allowed determining the amount of cancer-derived exosomes released from primary tumors into the bloodstream and visualizing the long-term homing behavior of exosomes to their target organs or tissues.
[Scientific Reports]
|
|
|
|
|
|
Researchers utilized baseline blood samples to identify metastatic castrate-resistant prostate cancer patients most likely to benefit from abiraterone plus prednisone (AAP) or enzalutamide.
[Prostate Cancer and Prostatic Diseases]
|
|
|
|
|
|
Oncolytic virus therapy can potentially overcome resistance to immunotherapy in prostate cancers by transforming cold tumors into ‘hot’, immune cell-infiltrated tumors. Scientists investigated whether the combination of intratumoral oncolytic reovirus, followed by targeted blockade of PD-1 checkpoint inhibition and/or the immunomodulatory CD73/Adenosine system could enhance anti-tumor immunity.
[Molecular Therapy-Oncolytics]
|
|
|
|
|
|
Laboratory studies were carried out in human metastatic castrate-resistant prostate cancer organoid cultures, prostate cancer cell lines, and mouse xenograft models. Epigenetic studies were carried out in a rapid autopsy cohort.
[JCO Precision Oncology]
|
|
|
|
|
|
|
|
Resistance to cancer therapy is a major barrier to cancer management. Conventional views have proposed that acquisition of resistance may result from genetic mutations. However, accumulating evidence implicates a key role of non-mutational resistance mechanisms underlying drug tolerance, the latter of which is the focus that is discussed here.
[Signal Transduction and Targeted Therapy]
|
|
|
|
|
|
|
|
Lantheus Holdings, Inc. has announced the submission of a New Drug Application to the US FDA for PyLâ„¢, a prostate specific membrane antigen-targeted positron emission tomography imaging agent for prostate cancer.
[Lantheus Holdings, Inc.]
|
|
|
|
|
|
|
|
January 9 – January 12, 2021
Lake Buena Vista, Florida, United States
|
|
|
|
|
|
|
|
|
|
|
City of Hope – Duarte, California, United States
|
|
|
|
|
|
|
University of Southern Denmark – Odense M, Denmark
|
|
|
|
|
|
|
University of Texas Southwestern Medical Center – Dallas, Texas, United States
|
|
|
|
|
|
|
Princess Margaret Cancer Center – Toronto, Ontario, Canada
|
|
|
|
|
|
|
University of Miami – Miami, Florida, United States
|
|
|
|
|
|